Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) EBT (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 16 years of EBT data on record, last reported at -$1.1 million in Q2 2025.

  • For Q2 2025, EBT rose 84.4% year-over-year to -$1.1 million; the TTM value through May 2025 reached -$38.7 million, down 506.5%, while the annual FY2025 figure was -$38.7 million, 506.5% down from the prior year.
  • EBT reached -$1.1 million in Q2 2025 per LFCR's latest filing, up from -$14.8 million in the prior quarter.
  • Across five years, EBT topped out at $15.5 million in Q2 2021 and bottomed at -$36.8 million in Q2 2023.
  • Average EBT over 5 years is -$5.6 million, with a median of -$6.9 million recorded in 2022.
  • Peak YoY movement for EBT: surged 3554.57% in 2021, then tumbled 823.03% in 2022.
  • A 5-year view of EBT shows it stood at $1.3 million in 2021, then crashed by 823.03% to -$9.2 million in 2022, then soared by 254.15% to $14.2 million in 2023, then plummeted by 146.05% to -$6.5 million in 2024, then surged by 82.94% to -$1.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$1.1 million in Q2 2025, -$14.8 million in Q1 2025, and -$6.5 million in Q4 2024.